Elyxyb remains a novel migraine therapy

By Brian Buntz | July 21, 2021

ELYXYB Dr. Reddy’s Laboratories Last year, FDA approved the celecoxib oral solution Elyxyb from Dr. Reddy’s Laboratories as an acute treatment of migraine with or without aura in adults. Formerly known as DFN-15, Elyxyb is a novel selective inhibitor of cyclooxygenase-2.

The company received FDA approval for the drug in May 2020.

The company formulated the drug as an oral solution using a self-micro emulsifying drug delivery system to optimize solubility and bioavailability.

Filed Under: Drug Discovery and Development, Neurological Disease
Tagged With: celecoxib, Dr. Reddy's Laboratories, ELYXYB, migraine

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.